of Schnider and colleagues 6 for propofol is used in routine practice.
But for obese patients, this PK model overestimates propofol clearance during maintenance because of a paradoxically decreased value of lean body mass calculated by the James 7 formula which appears to be flawed at high values of TBW. 8 9 For remifentanil, the lean body mass used in the PK model of Minto and colleagues 10 is calculated using the same formula. 7 The lean body mass is an important covariate of several PK parameters in the Minto and colleagues model, 10 in particular the central volume, the rapid peripheral volume of distribution, and the metabolic clearance were underestimated with the consequence that remifentanil is underdosed in obese patients. 11 12 Finally, for obese patients, specific propofol PK models have been developed 13 with age integrated as a relevant covariate. 14 The PK model of Minto can similarly be improved by calculating the true value of lean body mass using the formula of Janmahasatian and colleagues 12 15 or by calculating 'fictitious height'. 11 However, one difficulty with an isolated PK approach is that PD factors may also vary in lean or obese patients. 16 An alternative strategy is to titrate drug administration to a direct measure of hypnotic effect, for example, frontal electrocortical activity as determined by the bispectral index (BIS). 17 18 Moreover, the BIS change is sensitive for detecting the deficit of antinociception: noxious stimuli may cause electro-cortical activation such as haemodynamic change allowing the titration of analgesia. 19 We have developed and validated a dual closed-loop controller that automatically co-administers propofol and remifentanil solely guided by the BIS. 20 The closed-loop system has a cascade structure including a proportional-integral-derivative controller which steers a TCI system. Recently, the controller was used as an unbiased method for the determination of anaesthetic requirements in surgical patients, 21 -23 and this reproducible method has the potential to accurately determine anaesthetic requirements in obese patients. We thus used our BIS-guided dual-loop controller to determine propofol and remifentanil requirements during induction and maintenance of general anaesthesia in obese and lean surgical patients. In particular, we evaluated propofol and remifentanil consumption when the same controller was used in both groups without modification of the PK models or weight adjustment methods.
Methods
Our prospective two-centre, single-blind, cohort comparison with adaptive matching was approved by the French Ethics Committee (Comité Consultatif de Protection des Personnes dans la Recherche Biomédicale, Hô pital A. Paré, Boulogne Billancourt, France, N8 08 03 11). It was also approved by the French National Regulatory Office (Agence Française de Sécur-ité Sanitaire des Produits de Santé, N8 A80314-53). This study was registered at ClinicalTrials.gov (NCT00779844). Written informed consent was obtained from participating patients.
We enrolled adults undergoing elective upper-abdominal or bariatric laparoscopic procedures expected to last .60 min requiring general anaesthesia with tracheal intubation without combined regional anaesthesia. All were ASA physical status I-III. Exclusion criteria included psychiatric illness, supraspinal neurological disorders, a pacemaker, symptomatic gastro-oesophageal reflux, expected difficult airway management, or planned awake fibreoptic intubation. Obese patients were enrolled at the Hô pital Européen Georges Pompidou (Paris, France) and lean patients were enrolled at the Hô pital Foch (Suresnes, France).
Patients with a BMI .35 kg m 22 were enrolled in the obese group. Matched patients with a BMI,25 kg m 22 were enrolled in the lean group. The matching criteria were age (+10 yr) and sex. A preliminary analysis reported that the sex ratio was one male for four females for the obese patients and one male for one female in lean patients undergoing elective upperabdominal laparoscopic procedures. Thus, we decided to enrol one lean man for each obese man, and two lean women and one lean man for every three obese women allowing the inclusion of one lean patient within 30 days after the inclusion of one obese patient.
Procedures
No premedication was used except for 150 mg of cimetidine in the obese patients. Propofol and remifentanil were administered by identical closed-loop automated systems. Automated control was used during induction and throughout maintenance of general anaesthesia. TBW was set in the TCI systems of the controller using the PK model of Schnider and colleagues 6 for propofol and the PK model of Minto and colleagues 10 for remifentanil in both groups. The controller modifies the calculated effect-site drug concentrations using the TBW in both groups according to intraoperative BIS variations (Covidien, Dublin, Ireland). The dual-loop assumption is that small fluctuations of BIS are related to the intensity of noxious stimuli. 19 Small variations in BIS thus provoked changes only to remifentanil; but when the variation was large, both remifentanil and propofol were modified. The controller has previously been validated in lean patients in a randomized controlled study. 20 Details of the controller are provided in the Appendix. All investigators received a full day of training in the use of the automated controller at the Hôpital Foch, and were able to override the automated system if necessary, or to switch between automated and manual control. Upon arrival in the operating theatre, a dedicated i.v. cannula was inserted and routine monitoring started. Neuromuscular function at the adductor pollicis was monitored after loss of consciousness. Before induction, a BIS electrode (Zip Prep, Covidien) was positioned on the patient's forehead and connected to either an A-2000 XP (version 3.11) BIS monitor or a BIS M-Module (GE-Healthcare S/5 TM , Helsinki, Finland). Before induction, patients were pre-oxygenated with 100% oxygen through a face mask. In obese patients, a PEEP at 10 cm H 2 O was applied until end-tidal oxygen saturation .92% was obtained. In both groups, investigators chose the initial propofol effect-site target concentration according to their clinical judgement; in contrast, the initial remifentanil effect-site target concentration was determined by the controller. Lean patients were given atracurium to facilitate tracheal intubation, whereas a rapid-sequence induction with succinylcholine was used in obese patients.
After tracheal intubation, the lungs were mechanically ventilated with 40% inspired oxygen without nitrous oxide and a PEEP at 5 cm H 2 O. Atracurium was given to provide muscle relaxation throughout surgery in both groups. Other than administration of the study drugs, patient management was based on current standards of care. No specific recommendations were given for the treatment of haemodynamic abnormalities.
Approximately 45 min before the presumed end of surgery, i.v. analgesics were given to provide postoperative pain relief. Morphine, proparacetamol, nefopam, or non-steroidal antiinflammatory drugs were given at the discretion of the physician. In both weight groups, propofol and remifentanil were stopped simultaneously upon completion of surgery and all patients were ventilated with 100% oxygen before tracheal extubation.
Vasopressor or anti-hypertensive use was recorded. Recall of intraoperative events was evaluated by a standardized interview performed in the post-anaesthesia care unit and on the second or third postoperative day. 24 
Statistical analyses
Induction of anaesthesia was defined by the time elapsed between the beginning of propofol and remifentanil administration until BIS was ,60 for 30 s. The maintenance phase extended from this point until propofol and remifentanil administration was discontinued at the end of surgery.
The primary outcomes were propofol and remifentanil consumption during induction and maintenance of general anaesthesia. Consumption of each drug during each period was calculated in terms of TBW and in terms of IBW according to the following formula: IBW (kg)¼45.4 (49.9 if male)+0.89×(height in cm -152.4). 25 Secondary outcomes included the fraction of time in which patients demonstrated adequate anaesthesia, defined as BIS between 40 and 60 (BIS 40 -60 ), deep anaesthesia (BIS ,40 ), and light anaesthesia (BIS .60 ). Excessive anaesthesia was defined as the occurrence of suppression ratio with suppression ratio .10% lasting at least 1 min. 26 Data from the BIS monitor were recorded every 5 s.
In a previous study of lean patients during maintenance of general anaesthesia, propofol consumption was 4. patients, we expected that the controller would decrease propofol consumption by 30% calculated using the TBW. A minimum of 28 subjects per group was thus required to provide a 90% power for a two-sided error of 5%. Under the assumption that some patients would be excluded for various reasons, we planned a total of 64 patients. Categorical variables, expressed as numbers and frequencies, were compared using Fisher's exact test as appropriate. Continuous variables were described as the median and interquartile range (IQR) and compared using the Mann -Whitney U-test. Probability values of ,0.05 using two-tailed tests were considered statistically significant. Data analysis was performed using IBM-SPSS w version 20 (IBM-SPSS Science, Inc., Chicago, IL, USA).
Results
Among 70 patients who were approached, 64 were recruited between January 2009 and September 2011. Usable data were obtained from 30 patients in the obese group and 29 patients in the lean group (Fig. 1) . Baseline characteristics were similar except for TBW and BMI. In the obese group, only one patient among the 30 had a BMI,39 kg m 2 ( and induction data were presented in Table 2 . The median BIS values from induction to propofol and remifentanil discontinuation are presented in Figure 2 . During maintenance, propofol consumption calculated using the TBW was similar in each group (Table 3 and Fig. 3 ) but different when calculated using the IBW (Fig. 3) . Obese patients used half as much remifentanil as the lean patients when dose was expressed in terms of TBW. However, remifentanil consumption during maintenance anaesthesia was similar in each weight group when dose was expressed in terms of IBW (Table 3 and Fig. 3 ). The use of ephedrine and antihypertensive therapy was similar in each group (Table 3) . No cases of awareness with recall were reported.
The percentage of adequate anaesthesia and of deep or excessive anaesthesia was similar in the two groups, suggesting that the anaesthetic effect was similar in each weight group (Table 4) .
Discussion
Automated administration of anaesthetic agents guided by electro-cortical activity is well established 27 and has been successfully used during major surgery in patients with various co-morbidities, 20 26 28 -32 during cardiac surgery in adults 33 and paediatric patients, 34 during lung transplantation, 35 during pheochromocytoma resection, 36 during rigid bronchoscopy, 37 for deep sedation in intensive care units, 38 and for sedation in paediatric patients. 39 The use of an automated controller reduces episodes of excessive anaesthesia, and enhances predictability of tracheal extubation in lean patients. 20 28 We used BIS-guided automatic drug administration because it is an objective way to determine anaesthetic requirement which avoids largely unjustified assumptions about PK/PD that would otherwise be necessary when comparing drug use in obese and lean patients. Specifically, because the system was based on individual patient responses, the amounts of propofol and remifentanil given being based on individual requirements, it was probably independent of the underlying PK model but related to the gain constant of the controller. That the fraction of time with deep or excessive anaesthesia, the amount of burst suppression, and the use of vasopressors was similar in the obese and lean patients indicates that the controller provided a comparable anaesthetic effect in the obese and lean patients. Propofol requirements, based on TBW, were similar in obese and lean patients during induction of anaesthesia. The amount of propofol used during anaesthetic induction was 1.2 (1.1-1.6) mg kg 21 which was only slightly ,1.6 (0.2) mg kg 21 dose previously reported to achieve a BIS ,60 in 95% of patients. 40 It is towards the lower end of the propofol dose range for anaesthetic induction which ranges from 0.9 (0.1) 40 Propofol requirements, based on TBW, were also similar in obese and lean patients during anaesthetic maintenance. In both weight groups, propofol consumption was 5 mg kg 21 h 21 (Fig. 3A) which is consistent with previous recommendations for obese patients: 45 Table 5 summarizes propofol consumption in different clinical studies where consumption was related to the method of analgesia, type of surgery, or the use of brain monitoring. Our key result, though, is that propofol requirements, expressed as a function of TBW, are almost identical in obese and lean patients related to the increase in cardiac output, distribution volume, and propofol clearance by the liver were correlated to the TBW. 4 Clinicians should thus dose propofol in obese patients just as they usually do, based on TBW.
Remifentanil is a short-acting opioid agonist with an elimination half-life that is independent of infusion duration. 10 The dose of remifentanil for anaesthetic maintenance in obese patients ranges from 0.12 47 (Table 5 ). Remifentanil consumption in obese patients, calculated using TBW, was half what it was in the lean patients during both induction and maintenance. In contrast, the dose was nearly the same in each weight group when expressed in terms of lean body mass. This result is unsurprising, given that lean body mass is an important covariate for distribution volumes and clearances of remifentanil. 10 Our result extends previous PK analyses, 49 in that it is based on individual patient responses and thus includes both PK and potential PD effects of obesity. Finally, this study is in agreement with a previous study 49 that the remifentanil is best dosed using IBW. A limitation of our study is that the surgical procedures differed in the two groups. However, the magnitude and duration of the operations was comparable and it seems unlikely that anaesthetic requirement would otherwise much differ from two similar procedures.
Remifentanil titration was guided by electro-cortical activity rather than by haemodynamic changes, which are more often used in clinical practice. We chose BIS because painful stimulation does not reliably provoke haemodynamic responses in patients treated by anti-hypertensive therapy; furthermore, haemodynamic responses can be modified by vasopressor use, various preoperative or intraoperative treatments, blood loss, fluid administration, arrhythmia, heart failure, or manipulation of a great vessel. In particular, during laparoscopic procedures, a significant increase in mean arterial pressure has been reported after the increase in intra-abdominal pressure 50 which is a stimulator of vasopressin release 51 or hypercapnia induced by the CO 2 insufflations. 52 BIS guidance is thus more likely than arterial pressure or heart rate to identify true anaesthetic requirement during a laparoscopic procedure. A hypnotic like propofol and an analgesic like remifentanil can be combined in various ways. The relationship between the two study drugs in this study was determined by parameters Burst suppression 1 (3) 0 (0) 1 of our control system as reported previously. 20 We have previously shown that our controller provides consistent and stable anaesthesia under a variety of circumstances. 20 35 53 However, there are obviously a host of other potential combinations that may also work well and the current study cannot demonstrate that other combinations perform better or worse. The propofol-remifentanil relationship we used is thus one solution to the combination problem, but surely not the only one. It is possible that other combinations could yield different relationships between TBWand IBW in the obese. But the solution we propose, using TBW for propofol and IBW for remifentanil works well and provides a satisfactory anaesthetic. The continuous titration of the effect by an automated controller is feasible and reliable. It optimizes the titration of shortacting i.v. drugs and has probably the potential to improve care for obese patients. The use of the current automated controller guided by the electro-cortical activity demonstrated that the propofol doses in obese and lean patients were nearly identical when expressed as a function of TBW. In contrast, remifentanil doses were similar when expressed in terms of IBW. 
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